329 related articles for article (PubMed ID: 29019016)
1. Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections.
Ng SMS; Sioson JSP; Yap JM; Ng FM; Ching HSV; Teo JWP; Jureen R; Hill J; Chia CSB
Eur J Clin Microbiol Infect Dis; 2018 Jan; 37(1):141-148. PubMed ID: 29019016
[TBL] [Abstract][Full Text] [Related]
2. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
[TBL] [Abstract][Full Text] [Related]
3. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.
Chen A; Smith KP; Whitfield BA; Zucchi PC; Lasco TM; Bias TE; Kirby JE; Hirsch EB
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):365-367. PubMed ID: 28535946
[TBL] [Abstract][Full Text] [Related]
4. Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.
Thaden JT; Pogue JM; Kaye KS
Virulence; 2017 May; 8(4):403-416. PubMed ID: 27384881
[TBL] [Abstract][Full Text] [Related]
5. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.
Trecarichi EM; Tumbarello M
Virulence; 2017 May; 8(4):470-484. PubMed ID: 28276996
[TBL] [Abstract][Full Text] [Related]
7. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
[TBL] [Abstract][Full Text] [Related]
8. Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.
Ni W; Han Y; Liu J; Wei C; Zhao J; Cui J; Wang R; Liu Y
Medicine (Baltimore); 2016 Mar; 95(11):e3126. PubMed ID: 26986165
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial treatment challenges in the era of carbapenem resistance.
Peri AM; Doi Y; Potoski BA; Harris PNA; Paterson DL; Righi E
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):413-425. PubMed ID: 30905487
[TBL] [Abstract][Full Text] [Related]
10. Management of carbapenem-resistant Enterobacteriaceae infections.
Durante-Mangoni E; Andini R; Zampino R
Clin Microbiol Infect; 2019 Aug; 25(8):943-950. PubMed ID: 31004767
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions.
Nabarro LE; Veeraraghavan B
Eur J Clin Microbiol Infect Dis; 2015 Dec; 34(12):2307-11. PubMed ID: 26363636
[TBL] [Abstract][Full Text] [Related]
12. Review and mapping of carbapenem-resistant Enterobacteriaceae in Africa: Using diverse data to inform surveillance gaps.
Mitgang EA; Hartley DM; Malchione MD; Koch M; Goodman JL
Int J Antimicrob Agents; 2018 Sep; 52(3):372-384. PubMed ID: 29864500
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
Zavascki AP; Klee BO; Bulitta JB
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):519-526. PubMed ID: 28375030
[TBL] [Abstract][Full Text] [Related]
14. Options for treating carbapenem-resistant Enterobacteriaceae.
Rafailidis PI; Falagas ME
Curr Opin Infect Dis; 2014 Dec; 27(6):479-83. PubMed ID: 25259809
[TBL] [Abstract][Full Text] [Related]
15. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients.
Perez F; Van Duin D
Cleve Clin J Med; 2013 Apr; 80(4):225-33. PubMed ID: 23547093
[TBL] [Abstract][Full Text] [Related]
16. Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.
King M; Heil E; Kuriakose S; Bias T; Huang V; El-Beyrouty C; McCoy D; Hiles J; Richards L; Gardner J; Harrington N; Biason K; Gallagher JC
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483952
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation.
Patel G; Perez F; Bonomo RA
Curr Opin Organ Transplant; 2010 Dec; 15(6):676-82. PubMed ID: 20930636
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
Chiotos K; Hayes M; Gerber JS; Tamma PD
J Pediatric Infect Dis Soc; 2020 Feb; 9(1):56-66. PubMed ID: 31872226
[TBL] [Abstract][Full Text] [Related]
19. Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae.
Carrara E; Bragantini D; Tacconelli E
Curr Opin Infect Dis; 2018 Dec; 31(6):594-599. PubMed ID: 30299357
[TBL] [Abstract][Full Text] [Related]
20. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
